NovImmune raises $20.7M for mAb work

BZ Bank Aktiengesellschaft has led a $20.7 million Series B round of financing Geneva-based NovImmune. The company is developing therapeutic monoclonal antibodies for inflammatory diseases and immune-related disorders. Over the summer NovImmune inked a licensing deal with Genentech has for an inflammatory and autoimmune disease antibody.

"...[T]the current financing round allows NovImmune to generate proof-of-concept data with at least two compounds, increase the number of partnerships, and complete the validation of its proprietary bispecific antibody generation platform (kappa-lambdabodies)," said CEO Jack Barbut in a statement. The financing, he added, gives NovImmune a strong cash position in 2011 and allow the company to pursue other partnerships.

- here's NovImmune's release

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.